David Kendall, Zealand Pharma CMO
November 5, 2024 12:15 PM EST
R&D
Pharma

Zealand’s ‘as­pi­ra­tional’ mis­sion for its amylin drug to be first-line in obe­si­ty

Kyle LaHucik

Senior Reporter

SAN AN­TO­NIO — Zealand Phar­ma, hop­ing to cre­ate the next “foun­da­tion­al” ther­a­py for obe­si­ty, de­tailed more Phase 1 da­ta on its amylin ana­log that was the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times